Merck has announced that the US Food and Drug Administration (FDA) has sent a Complete Response Letter (CRL) regarding Merck’s supplemental Biologics License Application (sBLA) for the approval of KEYTRUDA.
The US Food and Drug Administration (FDA) grants orphan drug designation to Ambrx for ARX788, a homogeneous and highly stable antibody drug conjugate, for the treatment of HER2-positive gastric cancer.
The US Food and Drug Administration (FDA) has granted priority review for Merck’s New Drug Application (NDA) for the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan.
Enveric Biosciences has announced that it has signed an exclusive, perpetual licensing agreement with Diverse Biotech to develop new molecules for the treatment of cancer and other debilitating diseases.
Japan-based Takeda Pharmaceutical Company Limited has entered into an agreement to acquire private biopharmaceutical company Maverick Therapeutics, Inc. in a bid to expand its novel immuno-oncology portfolio.
The US Food and Drug Administration (FDA) has approved Libtayo to be used for the treatment of patients having two of the most common skin cancers in the US.
A new study claims palbociclib, an approved breast cancer drug, can treat an aggressive form of the cancer, bringing hope to thousands of afflicted women in the UK.
Chinese pharmaceutical company Innovent Biologics has signed an out-license agreement with Etana Biotechnologies to develop and commercialise cancer drug BYVASDA (Bevacizumab Biosimilar) in Indonesia.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.